Prostate cancer and PSA testing

One in seven men in the U.S. will be diagnosed with prostate cancer at some point in their lifetime, and one in thirty-five men will die from the disease.

The Prostate-Specific Antigen (PSA) Test, while not fool-proof, has been widely used to screen men for prostate cancer.

Since the U.S. Preventative Services Task Force released a recommendation stating that no one should receive PSA screening in 2012, there has been quite a bit of controversy surrounding the issue. However, three out of the four major organizations involved with prostate cancer screening and treatment recommendations still advocate the PSA screening for certain patient populations.

The team of medical experts within the Cone Health network recommends that men between the ages of 50 to 70 who have a ten year life expectancy or greater should still receive PSA screening. It is especially important for African American men and men with a family history of the disease that fall within this age range to get screened, as they are at higher risk for developing prostate cancer.

Since doctors began PSA screening, the incidence of prostate cancer deaths has decreased by 40 percent.

Our community is fortunate, as Cone Health has an exceptional network of primary care providers, urologists and oncology-related medical professionals dedicated to delivering the best quality care to patients with prostate cancer.

Spokesperson Background:

Dr. Ted Manny is a urologist at Alliance Urology and a member of the Cone Health medical Staff. Dr. Manny is a 2007 medical school graduate of the University of Texas Southwestern. He completed his residency in urology and a fellowship in robotics at Wake Forest University Baptist Medical Center.